Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
66 participants
Study Classification
OBSERVATIONAL
Study Start Date
2024-01-01
Study Completion Date
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this clinical trial is to investigate the early post-operative benefits of performing phacoemulsification at physiologic intraocular pressures. The main questions it aims to answer are:
* Is there less post operative corneal edema?
* Is there less post operative inflammation?
* Is the post operative vision better? Participants will undergo phacoemulsification cataract surgery with either high or low IOP settings Researchers will compare post op corneal edema, inflammatory marker levels and vision
* Is there less post operative corneal edema?
* Is there less post operative inflammation?
* Is the post operative vision better? Participants will undergo phacoemulsification cataract surgery with either high or low IOP settings Researchers will compare post op corneal edema, inflammatory marker levels and vision
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of Physiologic Cataract Surgery on Patient Comfort and Medication Usage
NCT07223866
Cataract and IOL Surgery
Cataract Surgery Anesthesia
Cataract Surgery Experience
+1 more
NOT_YET_RECRUITING
NA
Corneal Edema After Phacoemulsification
NCT03689270
Cataract
COMPLETED
IOP Changes Associated With SICS and Phako
NCT02642211
Cataract
Glaucoma
COMPLETED
EARLY_PHASE1
Proficiency of Eye Drop Instillation in Postoperative Cataract Patients in Ghana
NCT01181752
Cataract Surgery
UNKNOWN
Set up for in-Vivo Measurement of Dynamic Intraocular Pressure (IOP)
NCT00856141
Intraocular Pressure
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods:
Study population Inclusion Criteria
* Patients without prior ocular surgery both eyes
* Adult patients with visually significant cataract with WHO-World Health Organization NUC grade 2-3
* First eye only undergoing uncomplicated cataract surgery
* Unremarkable systemic history; controlled diabetes with HbA1c \<7%
* Unremarkable ocular health
* Anterior chamber depth ACD \>2.04mm10
* Age range 55-95
Exclusion Criteria:
* Prior ocular surgery including corneal refractive surgery, cataract surgery in fellow eye
* Thin corneas (\<490 microns)
* Complicated (use of pupil expansion devices) or prolonged cataract surgeries (\>15 mins) with post-operative complications (IOP spike \>30mmHg), severe punctate keratitis
Approximately 66 patients will be identified and included in the study. Patients at the day of surgery sign up will be randomized to high (65mmHg) vs low IOP (20mmHg) using a random online number generator; Even will be high IOP; Odd will be low IOP. Patients will undergo standard cataract surgery with equivalent vacuum and aspiration rates in both groups for the duration of the entire cataract surgery; IOP settings will be set at high vs low IOP but may be adjusted if necessary for the safety of the patient.
In all procedures, the intraocular lens (IOL) implanted and the ophthalmic viscosurgical device (OVD) materials used will be standardized to the same materials and are part of routine surgery. Cumulative dissipated energy (CDE) and surgical duration will be collected for all patients. An intraoperative aqueous sample 100-150µL will be collected at the end of the case 2 minutes after OVD removal and immediately transferred on dry ice to a laboratory, stored at -80°C until analysis as established in prior protocol. The extraction of aqueous sample will not require additional incisions.
All subjects will be prescribed the standard post-operative cataract surgery medications (not specific to study). Post-operative visits by the masked sub-investigator will perform the following procedures at 4hrs (early post-op), POD#1 (20-24hrs), POW#1:
Post-op Procedures Baseline Visit1 (4hrs) Visit2 (20-24hrs) Visit3 (1 week) Pachymetry X X X X Visual acuity BCVA UCVA/PHVA UCVA/PHVA UCVA/PHVA Slit Lamp- Cell /Flare X X X X
Pachymetry: a painless, simple test where a probe is gently placed on the front of the eye to measure the thickness of the cornea.
Best-corrected visual acuity (BCVA): this test is used to determine the smallest letters that can be read on a standardized chart. Un-corrected visual acuity (UCVA): the smallest letter that can be read unaided. Pinhole visual acuity (PHVA): the smallest letter that can be read without the interference of optical problems.
Slit lamp exam: a microscope is used to provide a magnified view of different parts of the eye and to determine inflammation (cell/flare) that is common with any ophthalmic surgery.
Visual acuity and slit lamp examinations are part of routine post-operative care.
Pachymetry measurements are for research purposes to determine if there's less corneal swelling after cataract surgery in the lower IOP group.
The primary end point is: difference in CCT post-op at 4 hours between High vs Low IOP groups.
Secondary endpoints include: CCT at POD#1 and POW#1, Cell/Flare at POHr4 and POD1, and inflammatory markers: levels of prostaglandin IL-6, IL-8, IL-Iβ, TNF-α, PGE2, MCP-1. Aqueous samples will be sent with de-identified patient information and aqueous analysis will be performed by the University of California, Irvine Molecular Biology and Biochemistry Labs. The laboratory will be masked to which treatment the subject received and will only provide the aqueous analysis report for the study.
Any adverse events (AE) will be recorded in subject's medical charts as well as an adverse event log. AEs are classified as serious or non-serious; expected or unexpected; and study-related, possibly study-related, or not study-related. Serious AEs will be reported immediately to the regulatory authorities as per standard of care. The potential risks involved are that of standard cataract surgery with potential complications and side effects associated with any surgical procedure. These include but are not limited to: infection, macular edema, increased IOP, general risk of anesthesia and surgery, bleeding in the eye, and decreased vision. Some potential benefits include: improved visual acuity, decreased glare symptoms, lowered IOP, and faster visual recovery.
Analysis:
Primary endpoint: Difference in mean CCT change at 4 hrs post-surgery between high vs low IOP will be assessed using t-test with a P-value \<0.05. Descriptive statistics will be used for the other secondary endpoints
Sample Size Justification:
The expected mean CCT change between the high vs low groups is hypothesized to be 32um, with a standard deviation of 40um. With a Type I/II error rate of alpha=0.05 and power=0.85, a sample size of 56 eyes are needed; additional 10 eyes to account for \~15 attrition; N=66
Data Collection and Management:
Data is recorded in a manner that reduces the risk of a breach of confidentiality. Password protected Microsoft Excel files will be utilized for this study and only accessible by authorized study personnel.
Ethical and Regulatory Considerations:
The study is conducted in accordance with the following:
Protocol and study-related plans and documents
* Local regulations, as applicable
* Good Clinical Practices, as outlined in the ICH Harmonized Tripartite Guideline for GCP (ICH
E6(R2))Ethical and Regulatory Considerations:
The study is conducted in accordance with the following:
* Protocol and study-related plans and documents
* Local regulations, as applicable
* Good Clinical Practices, as outlined in the ICH Harmonized Tripartite Guideline for CP (ICH E6(R2))
* The ethical principles established by the Declaration of Helsinki
* Regional participant data protection laws and regulations
* Local IRB requirements
Institutional Review Board (IRB):
The study site will maintain an accurate and complete record of all reports, documents and other submissions made to the Institutional Review Board (IRB) concerning this protocol.
The investigator must supply ongoing study progress reports to the IRB, per local requirements, protocol deviations and amendments. In addition, the investigator must notify the IRB at the closure of the study.
Informed Consent:
It is the responsibility of the investigator and clinical coordinator to inform each subject of the purpose of this study, including possible risks and benefits and document the informed consent process in the subject's chart. Prior to entry into the study or initiation of any study-related testing, the subject must read, sign and date the informed consent form. If the subject's vision is impaired to the point where they cannot read the informed consent document, the document will be read to the subject. The person executing the consent must also sign and date the consent form. One original informed consent form is to be retained by the study site and a copy is to be given to the subject.
Protocol Amendments:
This protocol must be followed as written. Any change or addition to this protocol that impacts subject safety, or the validity of the study requires a written protocol amendment that must be approved in writing by the IRB and any required regulatory authorities before implementation.
Record Keeping and Retention:
Data generated for the study should be stored in a limited-access file area and be accessible only to study personnel of the site. All reports and communications relating to study participants will identify participants only by subject identification number. Complete subject identification will be kept by the investigator. This information will be treated with strict adherence to professional standards of confidentiality.
The Investigator will retain a copy in the study file:
* A copy of the IRB approved informed consent form
* All original informed consent forms with required signatures
* All participant source documents, etc.
* All IRB correspondence (i.e., informed consent \[including any approved revisions\], protocol, AE, advertisements, newsletters).
Confidentiality:
All clinical study findings and documents are regarded as confidential. Study documents (protocols and other material) must be stored appropriately to ensure their confidentiality.
The anonymity of participants must be maintained per applicable local and national laws. Subjects are specified on all documents by subject number but not by name. Documents that identify the subject, e.g., the signed ICF, must be maintained in confidence by the investigator.
Study population Inclusion Criteria
* Patients without prior ocular surgery both eyes
* Adult patients with visually significant cataract with WHO-World Health Organization NUC grade 2-3
* First eye only undergoing uncomplicated cataract surgery
* Unremarkable systemic history; controlled diabetes with HbA1c \<7%
* Unremarkable ocular health
* Anterior chamber depth ACD \>2.04mm10
* Age range 55-95
Exclusion Criteria:
* Prior ocular surgery including corneal refractive surgery, cataract surgery in fellow eye
* Thin corneas (\<490 microns)
* Complicated (use of pupil expansion devices) or prolonged cataract surgeries (\>15 mins) with post-operative complications (IOP spike \>30mmHg), severe punctate keratitis
Approximately 66 patients will be identified and included in the study. Patients at the day of surgery sign up will be randomized to high (65mmHg) vs low IOP (20mmHg) using a random online number generator; Even will be high IOP; Odd will be low IOP. Patients will undergo standard cataract surgery with equivalent vacuum and aspiration rates in both groups for the duration of the entire cataract surgery; IOP settings will be set at high vs low IOP but may be adjusted if necessary for the safety of the patient.
In all procedures, the intraocular lens (IOL) implanted and the ophthalmic viscosurgical device (OVD) materials used will be standardized to the same materials and are part of routine surgery. Cumulative dissipated energy (CDE) and surgical duration will be collected for all patients. An intraoperative aqueous sample 100-150µL will be collected at the end of the case 2 minutes after OVD removal and immediately transferred on dry ice to a laboratory, stored at -80°C until analysis as established in prior protocol. The extraction of aqueous sample will not require additional incisions.
All subjects will be prescribed the standard post-operative cataract surgery medications (not specific to study). Post-operative visits by the masked sub-investigator will perform the following procedures at 4hrs (early post-op), POD#1 (20-24hrs), POW#1:
Post-op Procedures Baseline Visit1 (4hrs) Visit2 (20-24hrs) Visit3 (1 week) Pachymetry X X X X Visual acuity BCVA UCVA/PHVA UCVA/PHVA UCVA/PHVA Slit Lamp- Cell /Flare X X X X
Pachymetry: a painless, simple test where a probe is gently placed on the front of the eye to measure the thickness of the cornea.
Best-corrected visual acuity (BCVA): this test is used to determine the smallest letters that can be read on a standardized chart. Un-corrected visual acuity (UCVA): the smallest letter that can be read unaided. Pinhole visual acuity (PHVA): the smallest letter that can be read without the interference of optical problems.
Slit lamp exam: a microscope is used to provide a magnified view of different parts of the eye and to determine inflammation (cell/flare) that is common with any ophthalmic surgery.
Visual acuity and slit lamp examinations are part of routine post-operative care.
Pachymetry measurements are for research purposes to determine if there's less corneal swelling after cataract surgery in the lower IOP group.
The primary end point is: difference in CCT post-op at 4 hours between High vs Low IOP groups.
Secondary endpoints include: CCT at POD#1 and POW#1, Cell/Flare at POHr4 and POD1, and inflammatory markers: levels of prostaglandin IL-6, IL-8, IL-Iβ, TNF-α, PGE2, MCP-1. Aqueous samples will be sent with de-identified patient information and aqueous analysis will be performed by the University of California, Irvine Molecular Biology and Biochemistry Labs. The laboratory will be masked to which treatment the subject received and will only provide the aqueous analysis report for the study.
Any adverse events (AE) will be recorded in subject's medical charts as well as an adverse event log. AEs are classified as serious or non-serious; expected or unexpected; and study-related, possibly study-related, or not study-related. Serious AEs will be reported immediately to the regulatory authorities as per standard of care. The potential risks involved are that of standard cataract surgery with potential complications and side effects associated with any surgical procedure. These include but are not limited to: infection, macular edema, increased IOP, general risk of anesthesia and surgery, bleeding in the eye, and decreased vision. Some potential benefits include: improved visual acuity, decreased glare symptoms, lowered IOP, and faster visual recovery.
Analysis:
Primary endpoint: Difference in mean CCT change at 4 hrs post-surgery between high vs low IOP will be assessed using t-test with a P-value \<0.05. Descriptive statistics will be used for the other secondary endpoints
Sample Size Justification:
The expected mean CCT change between the high vs low groups is hypothesized to be 32um, with a standard deviation of 40um. With a Type I/II error rate of alpha=0.05 and power=0.85, a sample size of 56 eyes are needed; additional 10 eyes to account for \~15 attrition; N=66
Data Collection and Management:
Data is recorded in a manner that reduces the risk of a breach of confidentiality. Password protected Microsoft Excel files will be utilized for this study and only accessible by authorized study personnel.
Ethical and Regulatory Considerations:
The study is conducted in accordance with the following:
Protocol and study-related plans and documents
* Local regulations, as applicable
* Good Clinical Practices, as outlined in the ICH Harmonized Tripartite Guideline for GCP (ICH
E6(R2))Ethical and Regulatory Considerations:
The study is conducted in accordance with the following:
* Protocol and study-related plans and documents
* Local regulations, as applicable
* Good Clinical Practices, as outlined in the ICH Harmonized Tripartite Guideline for CP (ICH E6(R2))
* The ethical principles established by the Declaration of Helsinki
* Regional participant data protection laws and regulations
* Local IRB requirements
Institutional Review Board (IRB):
The study site will maintain an accurate and complete record of all reports, documents and other submissions made to the Institutional Review Board (IRB) concerning this protocol.
The investigator must supply ongoing study progress reports to the IRB, per local requirements, protocol deviations and amendments. In addition, the investigator must notify the IRB at the closure of the study.
Informed Consent:
It is the responsibility of the investigator and clinical coordinator to inform each subject of the purpose of this study, including possible risks and benefits and document the informed consent process in the subject's chart. Prior to entry into the study or initiation of any study-related testing, the subject must read, sign and date the informed consent form. If the subject's vision is impaired to the point where they cannot read the informed consent document, the document will be read to the subject. The person executing the consent must also sign and date the consent form. One original informed consent form is to be retained by the study site and a copy is to be given to the subject.
Protocol Amendments:
This protocol must be followed as written. Any change or addition to this protocol that impacts subject safety, or the validity of the study requires a written protocol amendment that must be approved in writing by the IRB and any required regulatory authorities before implementation.
Record Keeping and Retention:
Data generated for the study should be stored in a limited-access file area and be accessible only to study personnel of the site. All reports and communications relating to study participants will identify participants only by subject identification number. Complete subject identification will be kept by the investigator. This information will be treated with strict adherence to professional standards of confidentiality.
The Investigator will retain a copy in the study file:
* A copy of the IRB approved informed consent form
* All original informed consent forms with required signatures
* All participant source documents, etc.
* All IRB correspondence (i.e., informed consent \[including any approved revisions\], protocol, AE, advertisements, newsletters).
Confidentiality:
All clinical study findings and documents are regarded as confidential. Study documents (protocols and other material) must be stored appropriately to ensure their confidentiality.
The anonymity of participants must be maintained per applicable local and national laws. Subjects are specified on all documents by subject number but not by name. Documents that identify the subject, e.g., the signed ICF, must be maintained in confidence by the investigator.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Cataract
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High IOP setting
Traditional High (65mm Hg) IOP phacoemulsification settings
Cataract surgery at high IOP
Intervention Type
PROCEDURE
Cataract surgery at high IOP (conventional)
Low IOP Setting
Physiologic Low (20 mm Hg) IOP phacoemulsification settings
Cataract surgery at low IOP
Intervention Type
PROCEDURE
Cataract surgery at low IOP
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cataract surgery at high IOP
Cataract surgery at high IOP (conventional)
Intervention Type
PROCEDURE
Cataract surgery at low IOP
Cataract surgery at low IOP
Intervention Type
PROCEDURE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients without prior ocular surgery both eyes
* Adult patients with visually significant cataract with WHO-World Health Organization NUC grade 2-3
* First eye only undergoing uncomplicated cataract surgery
* Unremarkable systemic history; controlled diabetes with HbA1c \<7%
* Unremarkable ocular health
* Anterior chamber depth ACD \>2.04mm10
* Age range 55-95
* Adult patients with visually significant cataract with WHO-World Health Organization NUC grade 2-3
* First eye only undergoing uncomplicated cataract surgery
* Unremarkable systemic history; controlled diabetes with HbA1c \<7%
* Unremarkable ocular health
* Anterior chamber depth ACD \>2.04mm10
* Age range 55-95
Exclusion Criteria
* Prior ocular surgery including corneal refractive surgery, cataract surgery in fellow eye
* Thin corneas (\<490 microns)
* Complicated (use of pupil expansion devices) or prolonged cataract surgeries (\>15 mins) with post-operative complications (IOP spike \>30mmHg), severe punctate keratitis
* Thin corneas (\<490 microns)
* Complicated (use of pupil expansion devices) or prolonged cataract surgeries (\>15 mins) with post-operative complications (IOP spike \>30mmHg), severe punctate keratitis
Minimum Eligible Age
55 Years
Maximum Eligible Age
95 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alcon Research
INDUSTRY
Sponsor Role
collaborator
Wolfe Eye Clinic
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Edward Hsu Hu
Primary Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward H Hu, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Wolfe Eye Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wolfe Eye Clinic Cedar Rapids (Hiawatha)
Hiawatha, Iowa, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Cyril D, Brahmani P, Prasad S, Rashme VL, R S, Kamble NR, Balakrishnan L, Nagu K, Shekhar M. Comparison of two phacoemulsification system handpieces: prospective randomized comparative study. J Cataract Refract Surg. 2022 Mar 1;48(3):328-333. doi: 10.1097/j.jcrs.0000000000000769.
Reference Type
BACKGROUND
Vasavada AR, Praveen MR, Vasavada VA, Vasavada VA, Raj SM, Asnani PK, Garg VS. Impact of high and low aspiration parameters on postoperative outcomes of phacoemulsification: randomized clinical trial. J Cataract Refract Surg. 2010 Apr;36(4):588-93. doi: 10.1016/j.jcrs.2009.11.009.
Reference Type
BACKGROUND
Lundberg B, Jonsson M, Behndig A. Postoperative corneal swelling correlates strongly to corneal endothelial cell loss after phacoemulsification cataract surgery. Am J Ophthalmol. 2005 Jun;139(6):1035-41. doi: 10.1016/j.ajo.2004.12.080.
Reference Type
BACKGROUND
Suzuki H, Igarashi T, Takahashi H. Effect of a new phacoemulsification and aspiration handpiece on anterior chamber stability. J Cataract Refract Surg. 2023 Jan 1;49(1):91-96. doi: 10.1097/j.jcrs.0000000000001071.
Reference Type
BACKGROUND
Kaup S, Pandey SK. Cataract surgery in patients with Fuchs' endothelial corneal dystrophy. Community Eye Health. 2019;31(104):86-87. No abstract available.
Reference Type
BACKGROUND
Liu YC, Setiawan M, Ang M, Yam GHF, Mehta JS. Changes in aqueous oxidative stress, prostaglandins, and cytokines: Comparisons of low-energy femtosecond laser-assisted cataract surgery versus conventional phacoemulsification. J Cataract Refract Surg. 2019 Feb;45(2):196-203. doi: 10.1016/j.jcrs.2018.09.022. Epub 2018 Dec 6.
Reference Type
BACKGROUND
De Maria M, Iannetta D, Cimino L, Coassin M, Fontana L. Measuring Anterior Chamber Inflammation After Cataract Surgery: A Review of the Literature Focusing on the Correlation with Cystoid Macular Edema. Clin Ophthalmol. 2020 Jan 9;14:41-52. doi: 10.2147/OPTH.S237405. eCollection 2020.
Reference Type
BACKGROUND
Schultz T, Joachim SC, Kuehn M, Dick HB. Changes in prostaglandin levels in patients undergoing femtosecond laser-assisted cataract surgery. J Refract Surg. 2013 Nov;29(11):742-7. doi: 10.3928/1081597X-20131021-03.
Reference Type
BACKGROUND
Feng MT, Belin MW, Ambrosio R Jr, Grewal SP, Yan W, Shaheen MS, McGhee C, Maeda N, Neuhann TH, Burkhard Dick H, Alageel SA, Steinmueller A. Anterior chamber depth in normal subjects by rotating scheimpflug imaging. Saudi J Ophthalmol. 2011 Jul;25(3):255-9. doi: 10.1016/j.sjopt.2011.04.005. Epub 2011 Apr 30.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
83557125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Cataract Monitored Anesthesia Care (MAC) Feasibility Pilot Study
NCT06506669
ACTIVE_NOT_RECRUITING
NA
Outcomes of Phacoemulsification With Torsional Ultrasound
NCT01010490
COMPLETED
PHASE4
Intraocular Pressure Control Following One Site Versus Two Site Combined Phacoemulsification/IOL And Trabeculectomy
NCT00695747
COMPLETED
NA
Chronological Versus Non-chronological Phacoemulsification Training
NCT07337070
RECRUITING
NA
A Prospective Multicenter Study To Assess The Clinical Outcomes Of Current Phacoemulsification Approach To Cataract Extraction Versus The Micor System Device
NCT05729477
ENROLLING_BY_INVITATION
NA
Comparison of Two Phacoemulsification-methods: Low Fluidic EasyTip 2.2mm vs. High Fluidic EasyTip 2.2mm
NCT01936714
COMPLETED
NA
Posterior Capsulotomy in Cataract Complicated With Primary Posterior Capsule Opacification.
NCT03701139
UNKNOWN
NA
Corneal Endothelial Cell Loss After Phacoemulsification Compared With Extracapsular Cataract Extraction
NCT03262285
COMPLETED
Anterior Lens Capsule as a Spacer in the Deep Sclerectomy _ Phacoemulsification
NCT05906212
UNKNOWN
NA
Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery
NCT02096627
COMPLETED
To Evaluate IOL Position, Clinical Outcome of PanOptix in High Myopic Cataract Patients
NCT05042856
UNKNOWN
NA
Cataract Surgery in Patients With Pseudoexfoliation and Pseudoexfoliation Glaucoma
NCT04590651
UNKNOWN
NA
Less Discomfort and Less Pharmacology. Cataract Surgery at Physiologic Intraocular Pressure (IOP)
NCT06325397
COMPLETED
Comparison of Outcomes Between Femtosecond Laser-Assisted and Conventional Phacoemulsification in Fuchs Endothelial Corneal Dystrophy Patients With Cataracts
NCT06966167
RECRUITING
Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
NCT03184428
COMPLETED
Hydrus® Microstent New Enrollment Post-Approval Study
NCT04553523
RECRUITING
NA
IOP and Ocular Biometrics Changes After Phacoemulsification in Glaucoma Patients and Controls
NCT04334473
COMPLETED
NA
A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation
NCT02621840
COMPLETED
NA
Influencing Factors of the Corneal Endothelial Cell Loss
NCT05265832
COMPLETED
NA
Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
NCT02403206
COMPLETED
NA
Study on the Surgical Strategy of Corneal Endothelial Protection for Hard Nuclear Cataract Patients
NCT06991374
COMPLETED
NA
Effectiveness of Dry Eye Treatment With Diquafosol Sodium 3% After Phaco Surgery
NCT07122635
COMPLETED
Comfort Operative Ocular Light Study
NCT05085314
COMPLETED
NA
Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome
NCT02049333
COMPLETED
NA
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
NCT07222150
RECRUITING
NA